HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DAB(486)-interleukin 2

portions of diptheria toxin linked to IL-2; causes antigen specific immunosupression

Also Known As:

DAB(486)-IL-2; DAB486-IL-2; interleukin 2 toxin

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Glycosyltransferases: 784
      - Pentosyltransferases
        ADP Ribose Transferases: 198
        Diphtheria Toxin: 708
        DAB(486)-interleukin 2: 3
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Cytokines: 164289
    - Interleukins: 25257
      - Interleukin-2: 17447
        DAB(486)-interleukin 2: 3
    - Lymphokines: 811
      - Interleukin-2: 17447
        DAB(486)-interleukin 2: 3
- Biological Toxins: 20
  - Bacterial Toxins: 814
    - Diphtheria Toxin: 708
      - DAB(486)-interleukin 2: 3
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Interleukins: 25257
        Interleukin-2: 17447
        DAB(486)-interleukin 2: 3
      - Lymphokines: 811
        Interleukin-2: 17447
        DAB(486)-interleukin 2: 3
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - DAB(486)-interleukin 2: 3
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Interleukins: 25257
        Interleukin-2: 17447
        DAB(486)-interleukin 2: 3
      - Lymphokines: 811
        Interleukin-2: 17447
        DAB(486)-interleukin 2: 3

Related Diseases

1.	Neoplasms (Cancer) 01/01/1995 - "The results from the phase I/II studies of the intravenous administration of DAB486-IL-2 to patients with refractory haematological malignancies have now proven in principle the feasibility of fusion toxin therapy in man. "
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/01/1992 - "Taken together, these studies strongly support the concept that IL 2R-bearing T cells are essential for the induction of IDDM and suggest that DAB486-IL-2 would be a promising therapeutic approach in the treatment of human IDDM." 03/01/1992 - "We set DAB486-IL-2 the challenging task of preventing fulminant IDDM accelerated by the adoptive transfer of diabetic spleen cells. "
3.	Diphtheria 11/25/1990 - "Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194."

Related Drugs and Biologics

1.	Interleukin-2 (IL2)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Therapeutics